Most cited papers from AGO Austria

AGO Austria

What are the most cited papers from AGO Austria?

The most cited paper from AGO Austria is "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer" (Mansoor R. Mirza et al., 2016), with 2,495 citations. Next come "ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline" (936) and "Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage" (648).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 55 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer Mansoor R. Mirza et al. · New England Journal of Medicine Open access	8 Oct 2016	2,495
2	ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline Jean‐Marc Dumonceau, Christine Kapral, Lars Aabakken et al. · Endoscopy Open access	20 Dec 2019	936
3	Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage Bernhard Metzler, Peter Siostrzonek, Ronald K. Binder et al. · European Heart Journal Open access	8 Apr 2020	648
4	2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer Gavin C.E. Stuart, Henry Charles Kitchener, Monica A. Bacon et al. · International Journal of Gynecological Cancer Open access	Apr 2011	430
5	Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial Domenica Lorusso et al. · The Lancet	20 Mar 2024	398
6	Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial I. Ray-Coquard et al. · Annals of Oncology Open access	19 May 2023	364
7	Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study Klaus‐Peter Dieckmann et al. · Journal of Clinical Oncology Open access	15 Mar 2019	354
8	Outcomes and patterns of failure in solitary plasmacytoma: A multicenter Rare Cancer Network study of 258 patients Mahmut Özsahin, Richard W. C. Tsang, Philip M. Poortmans et al. · International Journal of Radiation OncologyBiologyPhysics	18 Oct 2005	281
9	Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial Gudrun H. Windbichler, Hubert Hausmaninger, Wolfgang Stummvoll et al. · British Journal of Cancer Open access	Mar 2000	245
10	Clinical Trials in Recurrent Ovarian Cancer Michael Leonard Friedlander et al. · International Journal of Gynecological Cancer Open access	Apr 2011	231
11	Monogenic variants in dystonia: an exome-wide sequencing study Michael Zech et al. · The Lancet Neurology Open access111 authors	21 Oct 2020	220
12	GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer György Kovács, Richard Pötter, Tillmann Loch et al. · Radiotherapy and Oncology	26 Oct 2004	206
13	European Headache Federation guideline on idiopathic intracranial hypertension Jan Hoffmann, Susan P. Mollan, Koen Paemeleire et al. · The Journal of Headache and Pain Open access	8 Oct 2018	195
14	Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer Peter Ulz, Jelena Belic, Ricarda Graf et al. · Nature Communications Open access	22 Jun 2016	172
15	Does Carotid Stent Cell Design Matter? Martin Schillinger, Manfred Gschwendtner, Bernhard Reimers et al. · Stroke	31 Jan 2008	160
16	Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry Simon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon et al. · Breast Cancer Research Open access	Dec 2021	157
17	From transformation to chronification of migraine: pathophysiological and clinical aspects Marta Torres‐Ferrús et al. · The Journal of Headache and Pain Open access	29 Apr 2020	155
18	Association of diet and headache Soodeh Razeghi Jahromi, Zeinab Ghorbani, Paolo Martelletti et al. · The Journal of Headache and Pain Open access	14 Nov 2019	155
19	Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup Ignace B. Vergote et al. · The Lancet Oncology Open access116 authors	25 Jul 2022	154
20	18F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients Mohsen Beheshti, Lukas Hehenwarter, Zeinab Paymani et al. · European Journal of Nuclear Medicine and Molecular Imaging Open access	7 Mar 2018	153
21	Detection of Pelvic Lymph Node Metastases in Patients With Clinically Localized Prostate Cancer: Comparison of [ 18 F]Fluorocholine Positron Emission Tomography-Computerized Tomography and Laparoscopic Radioisotope Guided Sentinel Lymph Node Dissection Axel Häcker, S. Jeschke, Karl Leeb et al. · The Journal of Urology	26 Oct 2006	140
22	Accelerated partial breast irradiation with multi-catheter brachytherapy: Local control, side effects and cosmetic outcome for 274 patients. Results of the German–Austrian multi-centre trial Oliver J. Ott, Guido Hildebrandt, Richard Pötter et al. · Radiotherapy and Oncology	29 Nov 2006	139
23	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease Georg Semmler et al. · Journal of Hepatology Open access	3 Dec 2021	137
24	Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis Sabine Spiegl‐Kreinecker, Daniela Lötsch, Bahil Ghanim et al. · Neuro-Oncology Open access	13 Feb 2015	137
25	Accelerated Partial Breast Irradiation: 5-Year Results of the German-Austrian Multicenter Phase II Trial Using Interstitial Multicatheter Brachytherapy Alone After Breast-Conserving Surgery Vratislav Strnad, Guido Hildebrandt, Richard Pötter et al. · International Journal of Radiation OncologyBiologyPhysics	4 Jun 2010	135
26	Refractory chronic cluster headache: a consensus statement on clinical definition from the European Headache Federation Dimos Dimitrios Mitsikostas, Lars IH Edvinsson, Rigmor Jensen et al. · The Journal of Headache and Pain Open access	27 Nov 2014	123
27	Refractory chronic migraine: a Consensus Statement on clinical definition from the European Headache Federation Paolo Martelletti, Zaza Katsarava, Christian Lampl et al. · The Journal of Headache and Pain Open access	28 Aug 2014	119
28	Does hysteroscopy facilitate tumor cell dissemination? Andreas Obermair, Magda Geramou, Fatih Güçer et al. · Cancer	2000	109
29	Posttraumatic anterior-inferior instability of the shoulder: arthroscopic findings and clinical correlations A. Spatschil, Franz Landsiedl, Werner Anderl et al. · Archives of Orthopaedic and Trauma Surgery	10 Oct 2005	109
30	Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer: A multicenter, prospective analysis Laurence H. Klotz, Giovanni Lughezzani, Davide Maffei et al. · Canadian Urological Association Journal Open access	17 Jul 2020	99
31	Internal Iliac Artery Embolization Before Endovascular Repair of Abdominal Aortic Aneurysms Maria Schoder, Luise Zaunbauer, Thomas Hölzenbein et al. · American Journal of Roentgenology	Sep 2001	96
32	LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) J-P. Machiels, Yungan Tao, Barbara Ann Burtness et al. · Annals of Oncology Open access	Sep 2022	95
33	Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial Philipp Harter, Marie Ange Mouret-Reynier, Sandro Pignata et al. · Gynecologic Oncology Open access	22 Dec 2021	93
34	Laparoscopic Radioisotope-Guided Sentinel Lymph Node Dissection in Staging of Prostate Cancer Stephan W. Jeschke, Avi Beri, Martin Grüll et al. · European Urology	29 Mar 2007	90
35	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial Ignace B. Vergote et al. · The Lancet Oncology Open access337 authors	8 May 2019	87
36	Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study Andreas Hochhaus et al. · Leukemia Open access	22 Jun 2020	83
37	Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet Joëlle Guilhot, Michele Baccarani, Richard E. Clark et al. · Blood	17 Apr 2012	82
38	Very Slow Creep Tests on Salt Samples P. Bérest, Hakim Gharbi, Benoît Brouard et al. · Rock Mechanics and Rock Engineering Open access	15 Mar 2019	81
39	ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer Christian Marth et al. · European Journal of Cancer	Dec 2016	80
40	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease Georg Semmler et al. · Hepatology Open access	13 Jul 2020	76
41	Functional Outcomes in Individuals Undergoing Very Early (< 5 h) and Early (5–24 h) Surgical Decompression in Traumatic Cervical Spinal Cord Injury: Analysis of Neurological Improvement from the Austrian Spinal Cord Injury Study Georg Mattiassich, Maria Gollwitzer, Franz Gaderer et al. · Journal of Neurotrauma	6 Jul 2017	76
42	Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy Astrid Pechmann et al. · Brain Open access153 authors	20 Jul 2022	75
43	Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma Michael Fridrik, Ulrich Jaeger, Andreas Leo Petzer et al. · European Journal of Cancer	15 Mar 2016	75
44	Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy Oliver Schwartz et al. · Archives of Pediatrics and Adolescent Medicine Open access283 authors	8 Apr 2024	73
45	Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial Antonio González-Martı́n et al. · European Journal of Cancer Open access	5 Sep 2022	73
46	Migraine and cluster headache – the common link Anne Luise Haulund Vollesen, Silvia Benemei, Francesca Natalia Cortese et al. · The Journal of Headache and Pain Open access	21 Sep 2018	73
47	Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis Sana Intidhar Labidi‐Galy, Manuel Jorge Rodrigues, José Luís Sandoval et al. · Annals of Oncology Open access	28 Nov 2022	71
48	Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial Sven� Mahner, Werner Meier, Andreas du Bois et al. · European Journal of Cancer	17 Dec 2014	71
49	Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP) Sebastian Willy Rehberg et al. · Intensive Care Medicine Open access	19 Sep 2024	69
50	Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV) Mattias Mandorfer et al. · Wiener klinische Wochenschrift Open access	26 Jun 2023	69

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.